Biocompatibility assessment of haemodialysis membrane materials by proteomic investigations


, V. Sirolli 1, L. Pieroni 2.3, S.L. Mortera 2.3, V. Greco 2.3,, M. Ronci 3.4.5, P. Felaco 1, G. Fucci 2, S. De Fulviis 1, R. Massoud 2, S. Condò 6, A.

Capria 6, N. Di Daniele 6, S. Bernardini 2, L. Amoroso 1, A. Urbani 2.3 e M. Bonomini 1.

1 Institute of Nephrology, Departement of Medicine, University "G. d'Annunzio", Chieti-Pescara, Italy; 2 Department of Experimental Medicine and Surgery, University "Tor Vergata", Rome, Italy; 3 IRCCS-Santa Lucia Foundation, Rome, Italy; 4 Department of Medical, Oral and Biotechnological Sciences, University G. D'Annunzio of Chieti-Pescara, Chieti, Italy; 5 Mawson Institute, University of South Australia, Mawson Lakes, SA, 5095 Australia ; 6 Department of System Medicine, University "Tor Vergata", Rome, Italy.

OBJECTIVES	METHODS
The exposure of blood to an artificial surface such as the	We examined and compared the blood protein adsorption patterns and coagulation profiles of
haemodialysis membrane results in the nearly instantaneous	two different membrane materials used for clinical haemodialysis in ESRD patients: CTA, a
deposition of a layer of plasma proteins. The composition of	chemically engineered modified cellulosic membrane, and the fully synthetic polymer
the protein layer profoundly influences all subsequent events,	polysulfone-based HE. Proteomics analysis was carried out on eluates from 3 male non-

and to a large extent determines the biocompatibility of the biomaterial [1-7]. In the present study, we examine the protein adsorption capacity and coagulation profiles of the polysulfonebased helixone material in comparison to cellulose triacetate. Shotgun proteomics data-independent analysis was applied to eluates obtained with each membrane after a dialysis session, in order to assess the function of desorbed proteins. diabetic haemodialysis patients; all patients had been on regular dialysis treatment and were on a stable intradialytic anticoagulation regimen (unfractionated heparin). Coagulation parameters (prothrombin time, partial thromboplastin time, fibrinogen) were measured before and after the haemodialysis session; Platelet aggregation testing was performed by a multiplate reader (Roche) using the TRAPtest, platelet stimulation via the thrombin receptor (TRAP-6) cascade, and the COLtest, collagen-induced aggregation. GpIIb/IIIa antagonist reagent was applied as a negative quality control.






Fig. 3 Percentage variation after-before dialysis session of coagulation parameters (upper panel) and correlations between fibrinogen concentration and partial thromboplastin time (lower panel) in patients undergoing haemodialysis with CTA membrane.




Fig. 4 Percentage variation after-before dialysis session of coagulation parameters (upper panel) and correlations between fibrinogen concentration and partial thromboplastin time (lower panel) in patients undergoing haemodialysis with HE membrane.

RESULTS

In this work, we analysed the biocompatibility of cellulose triacetate (CTA) and polysulfone-based helixone (HE) materials by means of a differential proteomics profiling experiment by data independent analysis based on a shotgun discovery proteomics method. We found an average of 65 proteins differentially adsorbed on the two membranes: most of the proteins retained by CTA belong to the extracellular matrix and extracellular region component and are involved in networks related to lipid metabolism, molecular transport, small molecule biochemistry, cellular assembly and organization, cell death and survival, and cardiovascular disease (Fig. 1 A and B) while HE membrane mostly retains a low abundance of plasma proteins belonging to macromolecular complexes, organelles, cell parts and a low level of proteins belonging to the extracellular matrix or extracellular regions howing their involvement in hematological disease, hereditary disorder, developmental disorder, organism injury and abnormalities, renal and urological disease, and molecular transport (Fig. 2 A and B). Concerning coagulation cascade, fibrinogen chains, serum amyloid proteins, insulin-like growth factor, and inhibin chains are more retained by the HE membrane, as well as for antithrombin and integrin (Fig 3 and 4). These data confirmed the retention on polysulfone-based HE membranes of proteins associated with the coagulation cascade, possibly suggesting an active role by this material in modulating this molecular mechanism.



References

 J. Mares, V. Thongboonkerd, Z. Tuma, J. Moravec and M. Matejovic, Kidney Int., 2009, 76, 404–413.
J. M. Anderson, T. L. Bonfield and N. P. Ziats, Int. J. Artif. Organs, 1990, 13, 375–382.
A. Sagripanti, A. Cupisti, U. Baicchi, M. Ferdeghini, E. Morelli and G. Barsotti, Nephron, 1993, 63, 273–278.
R. Johnson, Nephrol., Dial., Transplant., 1994, 9, 36–45.
R. D. Franck, J. Weber, H. Dresbach, H. Thelen, C. Weiss and J. Floege, Kidney Int., 2001, 60, 1972–1981.
W. H. Horl, J. Am. Soc. Nephrol., 2002, 13(suppl. 1), S62–S71.
L. Lucchi, G. Ligabue, M. Marietta, A. Delnevo, M. Malagoli, S. Perrone, L. Stipo, F. Grandi and A. Albertazzi, Artif. Organs, 2006, 30, 106–110.

Interfacial phenomena taking place on or in the material (adsorption and alteration of proteins) are crucial for biocompatibility and function since they can initiate complex cascade processes in the biological system. Identification of proteins surface-adsorbed onto the dialysis membrane material can thus provide important insights into reactions occurring during the haemodialysis procedure. We show here that the use of proteomic techniques may give valuable molecular and submolecular information on interfacial structures. Improved knowledge about the impact of biomaterial surface parameters upon interaction with plasma patients may hopefully lead to the development of more biocompatible polymers for the potential benefit of the uraemic patient.

Dialysis. Protein-energy wasting, inflammation and oxidative stress.

662-MP

Vittorio Sirolli

53 ERA

DOI: 10.3252/pso.eu.53era.2016

ePosters supported by F. Hoffmann- La Roche Ltd.



Poster SessionOnline